Identification and Quantitative Assessment of Uremic Solutes as Inhibitors of Renal Organic Anion Transporters, OAT1 and OAT3.

One of the characteristics of chronic kidney disease (CKD) is the accumulation of uremic solutes in the plasma. Less is known about the effects of uremic solutes on transporters that may play critical roles in pharmacokinetics. We evaluated the effect of 72 uremic solutes on organic anion transporter 1 and 3 (OAT1 and OAT3) using a fluorescent probe substrate, 6-carboxyfluorescein. A total of 12 and 13 solutes were identified as inhibitors of OAT1 and OAT3, respectively. Several of them inhibited OAT1 or OAT3 at clinically relevant concentrations and reduced the transport of other OAT1/3 substrates in vitro. Review of clinical studies showed that the active secretion of most drugs that are known substrates of OAT1/3 deteriorated faster than the renal filtration in CKD. Collectively, these data suggest that through inhibition of OAT1 and OAT3, uremic solutes contribute to the decline in renal drug clearance in patients with CKD.

[1]  A. Brandoni,et al.  Altered Renal Expression of Relevant Clinical Drug Transporters in Different Models of Acute Uremia in Rats. Role of Urea Levels , 2015, Cellular Physiology and Biochemistry.

[2]  H. Iwata,et al.  Human organic anion transporters function as a high-capacity transporter for p-cresyl sulfate, a uremic toxin , 2014, Clinical and Experimental Nephrology.

[3]  Imad Hanna,et al.  A Plasma Concentration of α-Ketoglutarate Influences the Kinetic Interaction of Ligands with Organic Anion Transporter 1 , 2014, Molecular Pharmacology.

[4]  A. Kosaka,et al.  Contribution of the organic anion transporter OAT2 to the renal active tubular secretion of creatinine and mechanism for serum creatinine elevations caused by cobicistat , 2014, Kidney international.

[5]  T. Abe,et al.  The kidney and uremic toxin removal: glomerulus or tubule? , 2014, Seminars in nephrology.

[6]  A. Więcek,et al.  The peptidic middle molecules: is molecular weight doing the trick? , 2014, Seminars in nephrology.

[7]  E. Hershberger,et al.  Impact of Renal Function on the Pharmacokinetics and Safety of Ceftolozane-Tazobactam , 2014, Antimicrobial Agents and Chemotherapy.

[8]  T. Ideker,et al.  Metabolomics reveals signature of mitochondrial dysfunction in diabetic kidney disease. , 2013, Journal of the American Society of Nephrology : JASN.

[9]  F. Müller,et al.  Transport of asymmetric dimethylarginine (ADMA) by cationic amino acid transporter 2 (CAT2), organic cation transporter 2 (OCT2) and multidrug and toxin extrusion protein 1 (MATE1) , 2013, Amino Acids.

[10]  L Zhang,et al.  Transporter Studies in Drug Development: Experience to Date and Follow‐Up on Decision Trees From the International Transporter Consortium , 2013, Clinical pharmacology and therapeutics.

[11]  K. Giacomini,et al.  Renal transporters in drug development. , 2013, Annual review of pharmacology and toxicology.

[12]  David S. Wishart,et al.  HMDB 3.0—The Human Metabolome Database in 2013 , 2012, Nucleic Acids Res..

[13]  Huijun Sun,et al.  Changes in expression of renal Oat1, Oat3 and Mrp2 in cisplatin-induced acute renal failure after treatment of JBP485 in rats. , 2012, Toxicology and applied pharmacology.

[14]  Raymond Vanholder,et al.  Normal and pathologic concentrations of uremic toxins. , 2012, Journal of the American Society of Nephrology : JASN.

[15]  Michael A Rose,et al.  A role for the organic anion transporter OAT3 in renal creatinine secretion in mice. , 2012, American journal of physiology. Renal physiology.

[16]  T. Niwa,et al.  Protein-bound uremic toxins in hemodialysis patients measured by liquid chromatography/tandem mass spectrometry and their effects on endothelial ROS production , 2012, Analytical and Bioanalytical Chemistry.

[17]  A. Ray,et al.  Renal drug–drug interactions: what we have learned and where we are going , 2012, Expert opinion on drug metabolism & toxicology.

[18]  K. Iwamoto,et al.  Interaction and transport of kynurenic acid via human organic anion transporters hOAT1 and hOAT3. , 2012, Pharmacological research.

[19]  M. Relling,et al.  Proximal Tubular Secretion of Creatinine by Organic Cation Transporter OCT2 in Cancer Patients , 2012, Clinical Cancer Research.

[20]  F. Leblond,et al.  Effects of Chronic Renal Failure on Kidney Drug Transporters and Cytochrome P450 in Rats , 2011, Drug Metabolism and Disposition.

[21]  Pär Matsson,et al.  Profiling of a prescription drug library for potential renal drug-drug interactions mediated by the organic cation transporter 2. , 2011, Journal of medicinal chemistry.

[22]  W. R. Wikoff,et al.  Untargeted metabolomics identifies enterobiome metabolites and putative uremic toxins as substrates of organic anion transporter 1 (Oat1). , 2011, Journal of proteome research.

[23]  J. Wetzels,et al.  Uremic Toxins Inhibit Transport by Breast Cancer Resistance Protein and Multidrug Resistance Protein 4 at Clinically Relevant Concentrations , 2011, PloS one.

[24]  H. Kusuhara,et al.  Prediction of Fluoroquinolone‐Induced Elevation in Serum Creatinine Levels: A Case of Drug–Endogenous Substance Interaction Involving the Inhibition of Renal Secretion , 2011, Clinical pharmacology and therapeutics.

[25]  R. Star,et al.  Major contribution of tubular secretion to creatinine clearance in mice. , 2010, Kidney international.

[26]  R. Draijer,et al.  The metabolic fate of red wine and grape juice polyphenols in humans assessed by metabolomics. , 2009, Molecular nutrition & food research.

[27]  Age K Smilde,et al.  Phenotyping tea consumers by nutrikinetic analysis of polyphenolic end-metabolites. , 2009, Journal of proteome research.

[28]  D. Schoenfeld,et al.  Phase 2 study of sodium phenylbutyrate in ALS , 2009, Amyotrophic lateral sclerosis : official publication of the World Federation of Neurology Research Group on Motor Neuron Diseases.

[29]  W. R. Wikoff,et al.  Multiple organic anion transporters contribute to net renal excretion of uric acid. , 2008, Physiological genomics.

[30]  K. Tomita,et al.  Altered Pharmacokinetics of Cationic Drugs Caused by Down-Regulation of Renal Rat Organic Cation Transporter 2 (Slc22a2) and Rat Multidrug and Toxin Extrusion 1 (Slc47a1) in Ischemia/Reperfusion-Induced Acute Kidney Injury , 2008, Drug Metabolism and Disposition.

[31]  T. Ogihara,et al.  Involvement of Uric Acid Transporters in Alteration of Serum Uric Acid Level by Angiotensin II Receptor Blockers , 2008, Pharmaceutical Research.

[32]  H. Endou,et al.  Elimination of Organic Anions in Response to an Early Stage of Renal Ischemia-Reperfusion in the Rat: Role of Basolateral Plasma Membrane Transporters and Cortical Renal Blood Flow , 2007, Pharmacology.

[33]  Osamu Ogawa,et al.  Substrate specificity of MATE1 and MATE2-K, human multidrug and toxin extrusions/H(+)-organic cation antiporters. , 2007, Biochemical pharmacology.

[34]  M. Malkin,et al.  Phase I dose escalation clinical trial of phenylbutyrate sodium administered twice daily to patients with advanced solid tumors , 2006, Investigational New Drugs.

[35]  Yuichi Sugiyama,et al.  Transporters as a determinant of drug clearance and tissue distribution. , 2006, European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences.

[36]  V. Vallon,et al.  Decreased Renal Organic Anion Secretion and Plasma Accumulation of Endogenous Organic Anions in OAT1 Knock-out Mice* , 2006, Journal of Biological Chemistry.

[37]  A. Tolcher,et al.  Phase I and pharmacokinetic study of pemetrexed administered every 3 weeks to advanced cancer patients with normal and impaired renal function. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[38]  F. Bellia,et al.  Simultaneous high performance liquid chromatographic separation of purines, pyrimidines, N-acetylated amino acids, and dicarboxylic acids for the chemical diagnosis of inborn errors of metabolism. , 2005, Clinical biochemistry.

[39]  W. S. St. Peter,et al.  Medication-related problems in ambulatory hemodialysis patients: a pooled analysis. , 2005, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[40]  Yuichi Sugiyama,et al.  A Species Difference in the Transport Activities of H2 Receptor Antagonists by Rat and Human Renal Organic Anion and Cation Transporters , 2005, Journal of Pharmacology and Experimental Therapeutics.

[41]  M. Otagiri,et al.  Renal Clearance of Endogenous Hippurate Correlates with Expression Levels of Renal Organic Anion Transporters in Uremic Rats , 2005, Journal of Pharmacology and Experimental Therapeutics.

[42]  I. Yano,et al.  Restored expression and activity of organic ion transporters rOAT1, rOAT3 and rOCT2 after hyperuricemia in the rat kidney. , 2005, Biochemical pharmacology.

[43]  M. Tuchman,et al.  Pharmacokinetics of sodium phenylacetate and sodium benzoate following intravenous administration as both a bolus and continuous infusion to healthy adult volunteers. , 2004, Molecular genetics and metabolism.

[44]  M. Satoh,et al.  Uremic Toxins Overload Accelerates Renal Damage in a Rat Model of Chronic Renal Failure , 2003, Nephron Experimental Nephrology.

[45]  A. Takeuchi,et al.  Decreased activity of basolateral organic ion transports in hyperuricemic rat kidney: roles of organic ion transporters, rOAT1, rOAT3 and rOCT2. , 2003, Biochemical pharmacology.

[46]  J. Jankowski,et al.  Increased plasma phenylacetic acid in patients with end-stage renal failure inhibits iNOS expression. , 2003, The Journal of clinical investigation.

[47]  R. Vanholder,et al.  New insights in uremic toxins. , 2003, Kidney international. Supplement.

[48]  A. Enomoto,et al.  Effects of oral adsorbent on gene expression profile in uremic rat kidney: cDNA array analysis. , 2003, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[49]  Hideyuki Saito,et al.  Down-regulation of rat organic cation transporter rOCT2 by 5/6 nephrectomy. , 2002, Kidney international.

[50]  G. Friedlander,et al.  Two apical multidrug transporters, P-gp and MRP2, are differently altered in chronic renal failure. , 2001, American journal of physiology. Renal physiology.

[51]  P. Ward,et al.  Clinical Pharmacokinetics of the Prodrug Oseltamivir and its Active Metabolite Ro 64-0802 , 1999, Clinical pharmacokinetics.

[52]  R. Vanholder,et al.  Pathophysiologic effects of uremic retention solutes. , 1999, Journal of the American Society of Nephrology : JASN.

[53]  R. Dixon,et al.  Lysophosphatidic acid-induced calcium mobilization and proliferation in kidney proximal tubular cells. , 1999, American journal of physiology. Renal physiology.

[54]  W. Keane,et al.  Pharmacokinetics of ceftibuten-cis and its trans metabolite in healthy volunteers and in patients with chronic renal insufficiency , 1991, Antimicrobial Agents and Chemotherapy.

[55]  K. Lynn,et al.  The pharmacokinetics and pharmacodynamics of quinapril and quinaprilat in renal impairment. , 1990, British journal of clinical pharmacology.

[56]  L. Benet,et al.  Differential effects of the degree of renal damage on p-aminohippuric acid and inulin clearances in rats , 1989, Journal of Pharmacokinetics and Biopharmaceutics.

[57]  J. Lin,et al.  Renal handling of drugs in renal failure. I: Differential effects of uranyl nitrate- and glycerol-induced acute renal failure on renal excretion of TEAB and PAH in rats. , 1988, The Journal of pharmacology and experimental therapeutics.

[58]  A. W. Asscher,et al.  Pharmacokinetics of ciprofloxacin in healthy volunteers and patients with impaired kidney function. , 1986, The Journal of antimicrobial chemotherapy.

[59]  F. Horber,et al.  Differential effect of impaired renal function on the kinetics of clavulanic acid and amoxicillin , 1986, Antimicrobial Agents and Chemotherapy.

[60]  M. Ohkawa,et al.  Elimination kinetics of ceftizoxime in humans with and without renal insufficiency , 1982, Antimicrobial Agents and Chemotherapy.

[61]  G. Amidon,et al.  Pharmacokinetics of cefazolin in normal and uremic subjects , 1974, Clinical pharmacology and therapeutics.

[62]  Jussi Paananen,et al.  Nontargeted metabolite profiling discriminates diet-specific biomarkers for consumption of whole grains, fatty fish, and bilberries in a randomized controlled trial. , 2015, The Journal of nutrition.

[63]  D. Solís.  US Food and Drug Administration , 2010 .

[64]  M. Jamei,et al.  A framework for assessing inter-individual variability in pharmacokinetics using virtual human populations and integrating general knowledge of physical chemistry, biology, anatomy, physiology and genetics: A tale of 'bottom-up' vs 'top-down' recognition of covariates. , 2009, Drug metabolism and pharmacokinetics.

[65]  B. Kearney,et al.  Pharmacokinetics and Dosing Recommendations of Tenofovir Disoproxil Fumarate in Hepatic or Renal Impairment , 2006, Clinical pharmacokinetics.

[66]  H. Kusuhara,et al.  Characterization of uremic toxin transport by organic anion transporters in the kidney. , 2004, Kidney international.

[67]  G. Hasenfuss,et al.  Pharmacokinetics of hydrochlorothiazide in relation to renal function , 2004, European Journal of Clinical Pharmacology.

[68]  Y. Yamamoto,et al.  Pharmacokinetics of famotidine, a new H2-receptor antagonist, in relation to renal function , 2004, European Journal of Clinical Pharmacology.

[69]  H. Endou,et al.  Urate transport via human PAH transporter hOAT1 and its gene structure. , 2003, Kidney international.

[70]  G. Schreiner,et al.  Contribution of proteinuria to progressive renal injury: consequences of tubular uptake of fatty acid bearing albumin. , 1993, American journal of nephrology.

[71]  M. Ohkawa,et al.  Elimination kinetics of cefotaxime and desacetyl cefotaxime in patients with renal insufficiency and during hemodialysis. , 1983, Chemotherapy.

[72]  S. Mackensen,et al.  The role of the interstitium of the renal cortex in renal disease. , 1979, Contributions to nephrology.